Study: NCT02363946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 % normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 % normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.